JP2014514346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514346A5 JP2014514346A5 JP2014509378A JP2014509378A JP2014514346A5 JP 2014514346 A5 JP2014514346 A5 JP 2014514346A5 JP 2014509378 A JP2014509378 A JP 2014509378A JP 2014509378 A JP2014509378 A JP 2014509378A JP 2014514346 A5 JP2014514346 A5 JP 2014514346A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- seq
- pharmaceutical
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 29
- 238000009472 formulation Methods 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229960004914 vedolizumab Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000004475 Arginine Substances 0.000 claims 9
- 229930006000 Sucrose Natural products 0.000 claims 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 9
- 239000005720 sucrose Substances 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 230000003796 beauty Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229940068968 polysorbate 80 Drugs 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481533P | 2011-05-02 | 2011-05-02 | |
| US61/481,533 | 2011-05-02 | ||
| US201161550545P | 2011-10-24 | 2011-10-24 | |
| US61/550,545 | 2011-10-24 | ||
| US201261585859P | 2012-01-12 | 2012-01-12 | |
| US61/585,859 | 2012-01-12 | ||
| PCT/US2012/036072 WO2012151248A2 (en) | 2011-05-02 | 2012-05-02 | FORMULATION FOR ANTI-α4β7 ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091845A Division JP6534415B2 (ja) | 2011-05-02 | 2017-05-02 | 抗α４β７抗体のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514346A JP2014514346A (ja) | 2014-06-19 |
| JP2014514346A5 true JP2014514346A5 (enExample) | 2016-10-20 |
| JP6190360B2 JP6190360B2 (ja) | 2017-08-30 |
Family
ID=46085207
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509378A Active JP6190360B2 (ja) | 2011-05-02 | 2012-05-02 | 抗α４β７抗体のための製剤 |
| JP2017091845A Active JP6534415B2 (ja) | 2011-05-02 | 2017-05-02 | 抗α４β７抗体のための製剤 |
| JP2018130978A Active JP6473845B2 (ja) | 2011-05-02 | 2018-07-10 | 抗α４β７抗体のための製剤 |
| JP2019074688A Active JP6878489B2 (ja) | 2011-05-02 | 2019-04-10 | 抗α４β７抗体のための製剤 |
| JP2021075479A Active JP7258941B2 (ja) | 2011-05-02 | 2021-04-28 | 抗α４β７抗体のための製剤 |
| JP2023061100A Active JP7492057B2 (ja) | 2011-05-02 | 2023-04-05 | 抗α４β７抗体のための製剤 |
| JP2024080117A Pending JP2024098027A (ja) | 2011-05-02 | 2024-05-16 | 抗α４β７抗体のための製剤 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091845A Active JP6534415B2 (ja) | 2011-05-02 | 2017-05-02 | 抗α４β７抗体のための製剤 |
| JP2018130978A Active JP6473845B2 (ja) | 2011-05-02 | 2018-07-10 | 抗α４β７抗体のための製剤 |
| JP2019074688A Active JP6878489B2 (ja) | 2011-05-02 | 2019-04-10 | 抗α４β７抗体のための製剤 |
| JP2021075479A Active JP7258941B2 (ja) | 2011-05-02 | 2021-04-28 | 抗α４β７抗体のための製剤 |
| JP2023061100A Active JP7492057B2 (ja) | 2011-05-02 | 2023-04-05 | 抗α４β７抗体のための製剤 |
| JP2024080117A Pending JP2024098027A (ja) | 2011-05-02 | 2024-05-16 | 抗α４β７抗体のための製剤 |
Country Status (42)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| HUE069586T2 (hu) | 2010-10-01 | 2025-03-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| CA2834900C (en) * | 2011-05-02 | 2021-03-02 | Millennium Pharmaceuticals, Inc. | Formulation for anti-.alpha.4.beta.7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| JP6189415B2 (ja) | 2012-04-02 | 2017-08-30 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| AU2014228172B2 (en) * | 2013-03-15 | 2018-12-06 | Abbvie Deutschland Gmbh & Co.Kg | Anti-EGFR antibody drug conjugate formulations |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| RU2689145C2 (ru) * | 2014-04-16 | 2019-05-24 | Биокон Лтд. | Стабильные белковые препараты, содержащие молярный избыток сорбитола |
| IL292655B2 (en) * | 2014-10-06 | 2024-03-01 | Chemocentryx Inc | CCR9 chemokine receptor inhibitor for use in a method for treating or reducing the development of inflammatory bowel diseases |
| US20170327584A1 (en) | 2014-11-26 | 2017-11-16 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the Treatment of Fistulizing Crohn's Disease |
| US20170360926A1 (en) * | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| CN113893341B (zh) * | 2015-08-11 | 2025-07-29 | 国立大学法人大阪大学 | 抗体 |
| WO2017087735A1 (en) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Method for treating crohn's disease |
| USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
| BR112018068628A2 (pt) * | 2016-03-14 | 2019-07-30 | Millennium Pharm Inc | método de prevenção de doença do enxerto contra hospedeiro |
| CN117298268A (zh) | 2016-03-14 | 2023-12-29 | 千禧制药公司 | 治疗或预防移植物抗宿主疾病的方法 |
| WO2017158393A1 (en) * | 2016-03-18 | 2017-09-21 | Oslo University Hospital Hf | Methods of treating graft-versus-host disease |
| MA44483A (fr) | 2016-03-24 | 2019-01-30 | Millennium Pharm Inc | Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| US20190060241A1 (en) * | 2016-04-13 | 2019-02-28 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| MA44864A (fr) | 2016-05-04 | 2019-03-13 | Icahn School Med Mount Sinai | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
| EP3468597A1 (en) | 2016-06-12 | 2019-04-17 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| TWI766890B (zh) * | 2016-10-07 | 2022-06-11 | 美商再生元醫藥公司 | 於室溫穩定之冷凍乾燥蛋白質 |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| PL3558391T3 (pl) * | 2016-12-23 | 2022-05-16 | Immunogen, Inc. | Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania |
| EP3615071A2 (en) | 2017-04-28 | 2020-03-04 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab) |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| AU2018274749B2 (en) * | 2017-05-26 | 2025-05-22 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of chronic pouchitis |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| ES2938608T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización |
| CN120241968A (zh) | 2017-10-12 | 2025-07-04 | 诺和诺德股份有限公司 | 用于药物治疗的司美鲁肽 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| EP3773696A4 (en) | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Stable formulations of therapeutic antibody |
| EP3773694A4 (en) | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Antibody formulation |
| CN112243379A (zh) * | 2018-04-10 | 2021-01-19 | 雷迪博士实验室有限公司 | 稳定的抗体制剂 |
| SG11202011651SA (en) | 2018-05-31 | 2020-12-30 | Ono Pharmaceutical Co | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| CN109239335A (zh) * | 2018-09-11 | 2019-01-18 | 广州万孚生物技术股份有限公司 | 联检试纸条及其制备方法 |
| WO2020123241A1 (en) * | 2018-12-10 | 2020-06-18 | Clear Creek Bio, Inc. | Multiphasic dosing regimens for treating cancer |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| JP7778567B2 (ja) * | 2019-04-17 | 2025-12-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
| CN119859188A (zh) * | 2019-06-10 | 2025-04-22 | 武田药品工业株式会社 | 产生抗α4β7抗体的方法 |
| CN118909121A (zh) * | 2019-06-10 | 2024-11-08 | 武田药品工业株式会社 | 抗体纯化方法及其组合物 |
| US20220267448A1 (en) * | 2019-06-10 | 2022-08-25 | Takeda Pharmaceutical Company Limited | Cell culture methods and compositions for antibody production |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| US20230093542A1 (en) | 2020-02-18 | 2023-03-23 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN113577281A (zh) * | 2020-04-30 | 2021-11-02 | 中国科学院分子细胞科学卓越创新中心 | 调控整合素β亚基的试剂和方法 |
| UY39327A (es) | 2020-07-16 | 2022-02-25 | Abbvie Inc | Anticuerpos anti- alpha-4-beta-7 |
| US20240100158A1 (en) * | 2021-01-20 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Freeze dried antibody formulations and methods thereof |
| EP4333878A4 (en) * | 2021-05-07 | 2025-03-19 | Dr. Reddy's Laboratories Limited | METHOD FOR IMPROVING THE STABILITY OF AN ANTIBODY FORMULATION |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| WO2024252368A2 (en) | 2023-06-09 | 2024-12-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for treating ulcerative colitis |
| WO2025133872A1 (en) * | 2023-12-19 | 2025-06-26 | Intas Pharmaceuticals Ltd. | Method for reducing oxidation levels in vedolizumab during cell culture process |
| WO2025149974A1 (en) | 2024-01-11 | 2025-07-17 | Takeda Pharmaceutical Company Limited | Combination therapy with an anti-alpha4beta7 antibody |
| WO2025177214A1 (en) | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US774216A (en) | 1903-11-19 | 1904-11-08 | Alexander F Ward | Machine for pointing and lapping hoops. |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
| US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
| DE3852236T2 (de) | 1987-08-11 | 1995-04-06 | Univ Leland Stanford Junior | Verfahren zur Kontrolle der Leukozyten-Extravasation. |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| EP0462111A4 (en) | 1988-12-23 | 1992-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Homing sequences and their uses |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| IL113261A (en) | 1989-09-01 | 1996-10-16 | Hutchinson Fred Cancer Res | Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2204890T3 (es) | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
| US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| DK0625912T3 (da) | 1992-02-12 | 1997-10-27 | Biogen Inc | Behandling af inflammatorisk tarmsygdom |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| WO1993023526A1 (en) | 1992-05-21 | 1993-11-25 | Center For Blood Research, Inc. | A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON |
| AU5732694A (en) | 1992-12-01 | 1994-06-22 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
| AU5675794A (en) | 1992-12-15 | 1994-07-04 | Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| AU688751B2 (en) | 1993-01-12 | 1998-03-19 | Biogen Idec Ma Inc. | Recombinant anti-VLA4 antibody molecules |
| JP3593343B2 (ja) | 1993-02-09 | 2004-11-24 | バイオジェン インコーポレイテッド | インシュリン依存型糖尿病の治療 |
| US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
| JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| DE122006000043I1 (de) | 1994-01-25 | 2007-02-15 | Elan Pharm Inc | Humanisierte Antik¦rper gegen das Leukozytenadh{sionsmolek}l vla-4 |
| US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
| US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
| GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| EP1409018B1 (en) | 2001-07-25 | 2010-01-06 | Facet Biotech Corporation | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| DE10163459A1 (de) | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| NZ535320A (en) | 2002-02-25 | 2008-05-30 | Elan Pharm Inc | Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation |
| WO2003099773A1 (en) | 2002-05-24 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| DE60314175T2 (de) | 2002-11-18 | 2008-01-24 | Chemocentryx Inc., Mountain View | Arylsulfonamide |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
| MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| MX2007002675A (es) | 2004-09-03 | 2007-06-11 | Genentech Inc | Antagonistas anti-beta7 humanizados y usos para los mismos. |
| WO2007061679A1 (en) | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| KR101317235B1 (ko) | 2006-04-21 | 2013-10-15 | 조마 테크놀로지 리미티드 | 길항제 항-ｃｄ40 항체 제약 조성물 |
| EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| ES2925992T3 (es) | 2006-10-20 | 2022-10-20 | Amgen Inc | Formulaciones estables de polipéptidos |
| US9193790B2 (en) | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
| PE20081477A1 (es) | 2006-12-11 | 2008-10-18 | Hoffmann La Roche | Formulacion liofilizada mab abeta |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| JP2010535771A (ja) * | 2007-08-08 | 2010-11-25 | アボット・ラボラトリーズ | 抗体を結晶化させるための組成物及び方法 |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| MY162752A (en) | 2009-03-20 | 2017-07-14 | Amgen Inc | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| MX2011013722A (es) * | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| CN109734807A (zh) | 2011-03-31 | 2019-05-10 | 豪夫迈·罗氏有限公司 | 施用β7整联蛋白拮抗剂的方法 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CA2834900C (en) | 2011-05-02 | 2021-03-02 | Millennium Pharmaceuticals, Inc. | Formulation for anti-.alpha.4.beta.7 antibody |
| US20170327584A1 (en) * | 2014-11-26 | 2017-11-16 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the Treatment of Fistulizing Crohn's Disease |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA44864A (fr) | 2016-05-04 | 2019-03-13 | Icahn School Med Mount Sinai | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
| EP3468597A1 (en) * | 2016-06-12 | 2019-04-17 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
-
2012
- 2012-02-05 UA UAA201313899A patent/UA116189C2/uk unknown
- 2012-05-02 MX MX2013012724A patent/MX348814B/es active IP Right Grant
- 2012-05-02 FI FIEP18150968.8T patent/FI3329965T3/fi active
- 2012-05-02 ES ES18150968T patent/ES3016382T3/es active Active
- 2012-05-02 PL PL18150968.8T patent/PL3329965T3/pl unknown
- 2012-05-02 RS RS20171014A patent/RS56397B1/sr unknown
- 2012-05-02 JP JP2014509378A patent/JP6190360B2/ja active Active
- 2012-05-02 KR KR1020187033652A patent/KR102096484B1/ko active Active
- 2012-05-02 KR KR1020187012689A patent/KR101923378B1/ko active Active
- 2012-05-02 HU HUE12721093A patent/HUE036663T2/hu unknown
- 2012-05-02 IL IL296838A patent/IL296838A/en unknown
- 2012-05-02 TW TW101115712A patent/TWI556828B/zh active
- 2012-05-02 AR ARP120101539A patent/AR086237A1/es not_active Application Discontinuation
- 2012-05-02 GE GEAP201213304A patent/GEP201706734B/en unknown
- 2012-05-02 AU AU2012250873A patent/AU2012250873B2/en active Active
- 2012-05-02 DK DK18150968.8T patent/DK3329965T3/da active
- 2012-05-02 KR KR1020217020871A patent/KR102465394B1/ko active Active
- 2012-05-02 DK DK12721093.8T patent/DK2704798T3/en active
- 2012-05-02 UA UAA201707804A patent/UA126545C2/uk unknown
- 2012-05-02 PL PL12721093T patent/PL2704798T3/pl unknown
- 2012-05-02 PH PH1/2013/502236A patent/PH12013502236A1/en unknown
- 2012-05-02 CN CN201711161579.XA patent/CN108079291B/zh active Active
- 2012-05-02 BR BR112013028424-2A patent/BR112013028424A2/pt not_active Application Discontinuation
- 2012-05-02 MY MYPI2013003922A patent/MY172735A/en unknown
- 2012-05-02 TW TW105130046A patent/TWI664978B/zh active
- 2012-05-02 IL IL296847A patent/IL296847A/en unknown
- 2012-05-02 PE PE2018001579A patent/PE20190405A1/es unknown
- 2012-05-02 HU HUE18150968A patent/HUE071510T2/hu unknown
- 2012-05-02 HR HRP20250472TT patent/HRP20250472T1/hr unknown
- 2012-05-02 RS RS20250372A patent/RS66809B1/sr unknown
- 2012-05-02 IL IL275038A patent/IL275038B2/en unknown
- 2012-05-02 HR HRP20171432TT patent/HRP20171432T1/hr unknown
- 2012-05-02 KR KR1020137031382A patent/KR20140145953A/ko not_active Ceased
- 2012-05-02 EP EP24167556.0A patent/EP4378484A3/en active Pending
- 2012-05-02 PT PT127210938T patent/PT2704798T/pt unknown
- 2012-05-02 SI SI201232089T patent/SI3329965T1/sl unknown
- 2012-05-02 CA CA3028209A patent/CA3028209C/en active Active
- 2012-05-02 PT PT181509688T patent/PT3329965T/pt unknown
- 2012-05-02 ME MEP-2017-228A patent/ME02859B/me unknown
- 2012-05-02 SM SM20170508T patent/SMT201700508T1/it unknown
- 2012-05-02 EP EP18150968.8A patent/EP3329965B1/en active Active
- 2012-05-02 EP EP12721093.8A patent/EP2704798B1/en active Active
- 2012-05-02 KR KR1020227038842A patent/KR20220154834A/ko not_active Ceased
- 2012-05-02 LT LTEP18150968.8T patent/LT3329965T/lt unknown
- 2012-05-02 SM SM20250218T patent/SMT202500218T1/it unknown
- 2012-05-02 UY UY0001034053A patent/UY34053A/es not_active Application Discontinuation
- 2012-05-02 PH PH1/2018/500030A patent/PH12018500030B1/en unknown
- 2012-05-02 TW TW107138209A patent/TWI664980B/zh active
- 2012-05-02 MX MX2018003210A patent/MX383317B/es unknown
- 2012-05-02 MY MYPI2016001847A patent/MY183471A/en unknown
- 2012-05-02 US US13/462,414 patent/US20120282249A1/en not_active Abandoned
- 2012-05-02 CN CN201711310404.0A patent/CN108129565B/zh active Active
- 2012-05-02 EA EA201391614A patent/EA032729B1/ru not_active IP Right Cessation
- 2012-05-02 EP EP17180246.5A patent/EP3263178A1/en active Pending
- 2012-05-02 WO PCT/US2012/036072 patent/WO2012151248A2/en not_active Ceased
- 2012-05-02 CN CN201280030450.4A patent/CN103608071B/zh active Active
- 2012-05-02 PE PE2013002431A patent/PE20141175A1/es active IP Right Grant
- 2012-05-02 MX MX2016012776A patent/MX356827B/es unknown
- 2012-05-02 LT LTEP12721093.8T patent/LT2704798T/lt unknown
- 2012-05-02 SI SI201231073T patent/SI2704798T1/sl unknown
- 2012-05-02 SG SG2013079686A patent/SG194652A1/en unknown
- 2012-05-02 KR KR1020257019984A patent/KR20250094743A/ko active Pending
- 2012-05-02 ES ES12721093.8T patent/ES2645187T3/es active Active
- 2012-05-02 KR KR1020207008950A patent/KR102275603B1/ko active Active
- 2012-05-02 CA CA2834867A patent/CA2834867C/en active Active
- 2012-05-02 KR KR1020177027571A patent/KR101923371B1/ko active Active
- 2012-05-02 US US14/114,832 patent/US9764033B2/en active Active
- 2012-05-02 CN CN201711309462.1A patent/CN108187042A/zh active Pending
-
2013
- 2013-10-28 IL IL229104A patent/IL229104A0/en unknown
- 2013-10-29 ZA ZA2013/08069A patent/ZA201308069B/en unknown
- 2013-10-30 DO DO2013000253A patent/DOP2013000253A/es unknown
- 2013-10-30 CL CL2013003146A patent/CL2013003146A1/es unknown
- 2013-10-31 MX MX2021006723A patent/MX2021006723A/es unknown
- 2013-11-01 CO CO13259825A patent/CO6801647A2/es not_active Application Discontinuation
- 2013-11-26 EC ECSP13013050 patent/ECSP13013050A/es unknown
- 2013-11-26 MA MA36501A patent/MA35136B1/fr unknown
- 2013-12-19 CR CR20130677A patent/CR20130677A/es unknown
-
2016
- 2016-07-20 US US15/215,012 patent/US9663579B2/en active Active
- 2016-07-20 US US15/214,993 patent/US10143752B2/en active Active
- 2016-07-20 US US15/215,000 patent/US10004808B2/en active Active
- 2016-09-19 AU AU2016231469A patent/AU2016231469B2/en active Active
-
2017
- 2017-04-05 CL CL2017000830A patent/CL2017000830A1/es unknown
- 2017-05-02 JP JP2017091845A patent/JP6534415B2/ja active Active
- 2017-08-16 US US15/678,744 patent/US20190076532A1/en not_active Abandoned
- 2017-10-11 CY CY20171101056T patent/CY1119435T1/el unknown
- 2017-10-20 ZA ZA2017/07158A patent/ZA201707158B/en unknown
-
2018
- 2018-03-20 US US15/927,032 patent/US20180207279A1/en not_active Abandoned
- 2018-06-21 HK HK18107977.2A patent/HK1249466A1/en unknown
- 2018-06-21 US US16/015,167 patent/US20180289811A1/en not_active Abandoned
- 2018-07-10 JP JP2018130978A patent/JP6473845B2/ja active Active
- 2018-10-18 ZA ZA2018/06946A patent/ZA201806946B/en unknown
- 2018-12-03 US US16/208,294 patent/US20190231878A1/en active Pending
- 2018-12-11 AU AU2018278866A patent/AU2018278866B2/en active Active
-
2019
- 2019-03-20 AU AU2019201926A patent/AU2019201926A1/en not_active Abandoned
- 2019-04-10 JP JP2019074688A patent/JP6878489B2/ja active Active
- 2019-06-26 IL IL267668A patent/IL267668B/en active IP Right Grant
- 2019-12-23 US US16/726,092 patent/US12171832B2/en active Active
-
2020
- 2020-01-15 US US16/743,813 patent/US12053526B2/en active Active
- 2020-02-13 PH PH12020500336A patent/PH12020500336A1/en unknown
- 2020-10-08 AU AU2020250249A patent/AU2020250249B2/en active Active
-
2021
- 2021-04-28 JP JP2021075479A patent/JP7258941B2/ja active Active
-
2022
- 2022-02-22 US US17/652,090 patent/US20220370617A1/en active Pending
- 2022-04-29 EC ECSENADI202234515A patent/ECSP22034515A/es unknown
- 2022-09-15 AU AU2022231726A patent/AU2022231726B2/en active Active
-
2023
- 2023-04-05 JP JP2023061100A patent/JP7492057B2/ja active Active
-
2024
- 2024-05-16 JP JP2024080117A patent/JP2024098027A/ja active Pending
- 2024-07-19 US US18/778,906 patent/US20250000981A1/en active Pending
- 2024-10-21 US US18/922,371 patent/US20250041424A1/en active Pending
-
2025
- 2025-04-04 AU AU2025202434A patent/AU2025202434A1/en active Pending
- 2025-05-29 US US19/222,996 patent/US20250288679A1/en active Pending
- 2025-06-05 US US19/230,064 patent/US20250295786A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514346A5 (enExample) | ||
| JP2014515763A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| KR102359181B1 (ko) | 항-ｒｓｖ 모노클로날 항체 제제 | |
| JP2021504372A5 (enExample) | ||
| IL274846B1 (en) | FORMULATION FOR ANTI-a4b7 ANTIBODY | |
| JP2016515511A5 (enExample) | ||
| JP2020518599A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| JP2021501214A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| JP2018076350A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| TW202005981A (zh) | 高親和性、異構體選擇性之TGFβ1抑制劑及其用途 | |
| JP2006522830A5 (enExample) | ||
| JP2018507202A (ja) | モノクローナル抗体のための安定的な液体製剤 | |
| JP2013543505A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| JP2014522843A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2016508973A5 (enExample) | ||
| JP2019509311A5 (enExample) | ||
| JP2019520316A5 (enExample) |